Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Wacker steps up mRNA capacity in Germany

by Alex Scott
June 13, 2024 | A version of this story appeared in Volume 102, Issue 18

 

A person in clean-room attire working over a large stainless steel tank.
Credit: Wacker Chemie
Wacker's new messenger RNA facility in Halle, Germany

Wacker Chemie, the German specialty chemicals firm, has opened a new facility for making messenger RNA (mRNA)–based active ingredients for medicines such as vaccines and cancer drugs at its site in Halle, Germany. The facility, which cost over $100 million, has four mRNA production lines. It more than triples Wacker’s production capacity at Halle, to over 200 million vaccine doses annually. The company plans to open a biotech center in Munich later this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.